✦ LIBER ✦

Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival

✍ Scribed by Rishi Nayyar; Nitin Sharma; Narmada P Gupta

Book ID: 108978007
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 168 KB
Volume: 16
Category: Article
ISSN: 0919-8172
DOI: 10.1111/j.1442-2042.2009.02351.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Editorial Comment to docetaxel-based com

Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival

✍ Takeshi Yuasa 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

Docetaxel and zoledronic acid in patient

Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer

✍ Dimitri Vordos; Bernard Paule; Francis Vacherot; Yves Allory; Laurent Salomon; A 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Response to docetaxel/carboplatin-based

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer

✍ Mari Nakabayashi; Oliver Sartor; Susanna Jacobus; Meredith M. Regan; David McKea 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Combination chemotherapy with weekly doc

Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients

✍ Atsushi Takenaka; Yuji Yamada; Toshifumi Kurahashi; Hideo Soga; Hideaki Miyake; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

Activity of second-line chemotherapy in

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone

✍ Jonathan E. Rosenberg; Vivian K. Weinberg; W. Kevin Kelly; Dror Michaelson; Maha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 1 views

## Abstract ## BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second‐line chemotherapy for taxane‐refractory, hormone‐refractory, prostate cancer (HRPC). ## METHODS. Patients with HRPC that progressed during or wi

First- and second-line chemotherapy with

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer : Does sequence matter?

✍ Jorg Michels; Trina Montemurro; Nevin Murray; Christian Kollmannsberger; Kim Ngu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views